Étiquette : addiction opiacés

Emerging Evidence for Cannabis’ Role in Opioid Use Disorder, Beth Wiese and Adrianne R. Wilson-Poe, 2018

Emerging Evidence for Cannabis’ Role in Opioid Use Disorder Beth Wiese and Adrianne R. Wilson-Poe Cannabis and Cannabinoid Research, 2018, Volume 3.1,179-189. Doi : 10.1089/can.2018.0022   Abstract Introduction : The opioid epidemic has become an immense problem in North America, and despite decades of research on the most effective means to treat opioid use disorder (OUD), overdose deaths are at an all-time high, and relapse remains pervasive. Discussion : Although there are a number of FDA-approved opioid replacement therapies and maintenance medications to help ease the severity of opioid withdrawal symptoms and aid in relapse prevention, these medications are not risk free nor are they successful for [...]

Lire la suite

Associations of Parental Marijuana Use With Offspring Marijuana, Tobacco, and Alcohol Use and Opioid Misuse, Bertha K. Madras et al., 2019

Associations of Parental Marijuana Use With Offspring Marijuana, Tobacco, and Alcohol Use and Opioid Misuse Bertha K. Madras, Beth Han, Wilson M. Compton, Christopher M. Jones, Elizabeth I. Lopez, Elinore F. McCance-Katz JAMA Network Open, 2019, 2, (11), e1916015. doi : 10.1001/jamanetworkopen.2019.16015 Abstract IMPORTANCE : Marijuana use is increasing among adults and often co-occurs with other substance use; therefore, it is important to examine whether parental marijuana use is associated with elevated risk of substance use among offspring living in the same household. OBJECTIVE : To examine associations of parental marijuana use with offspring marijuana, tobacco, and alcohol use and opioid misuse. DESIGN, SETTING, AND PARTICIPANTS : [...]

Lire la suite

Cannabis use, pain and prescription opioid use in people living with chronic non-cancer pain : Findings from a four-year prospective cohort, Gabrielle Campbell et al., 2018

Cannabis use, pain and prescription opioid use in people living with chronic non-cancer pain : Findings from a four-year prospective cohort Gabrielle Campbell, Wayne D. Hall, Amy Peacock, Nicholas Lintzeris, Raimondo Bruno, Briony Larance, Suzanne Nielsen, Milton Cohen, Gary Chan, Richard P. Mattick, Fiona Blyth, Marian Shanahan, Timothy Dobbins, Michael Farrell, Louisa Degenhardt Lancet Public Health, 2018, 3, (7): e341–e350. doi:10.1016/S2468-2667(18)30110-5.   Abstract Background : There has been growing interest in the use of cannabis and cannabinoids to treat chronic non-cancer pain (CNCP). Cannabis and cannabinoids have attracted attention because of their greater safety compared with opioids, and the possibility that their use can reduce opioid [...]

Lire la suite

The effect of cannabis laws on opioid use, J.L. Flexon et al., 2019

The effect of cannabis laws on opioid use. J.L. Flexon, L. Stolzenberg, S.J. d'Alessio International Journal of Drug Policy, 2019, 74, 152-159. doi : 10.1016/j.drugpo.2019.09.013. Abstract BACKGROUND : Many Americans rely on opioids at varying dosages to help ameliorate their suffering. However, empirical evidence is mounting that opioids are ineffective at controlling non-cancer related chronic pain, and many argue the strategies meant to relieve patient suffering are contributing to the growing opioid epidemic. Concurrently, several states now allow the use of medical cannabis to treat a variety of medical conditions, including chronic pain. Needing more exploration is the impact of cannabis laws on general opioid reliance [...]

Lire la suite

Ayahuasca for Addiction ? That’s a Trip, Adi Jaffe, 2018

Ayahuasca for Addiction ? That's a Trip Ayahuasca has long been used to heal the spirit, so what about addiction? Adi Jaffe, Psychology Today Posted Dec 10, 2018 https://www.psychologytoday.com/us/blog/all-about-addiction/201812/ayahuasca-addiction-thats-trip   Doctors have been prescribing drugs to treat substance addictions for decades. Most commonly known is the use of buprenorphine and naloxone (Suboxone) in opioid addiction which provides some opioid activation, helping with withdrawal and cravings, without the same “high” and many of the associated psychosocial effects of illicit drug use. But Suboxone isn’t the only one – methadone, modafinil, naltrexone, ketamine, and many more examples exist in which the use of a chemical has been prescribed to help [...]

Lire la suite

Clinicians’ Guide to Cannabidiol and Hemp Oils, Harrison J. VanDolah et al., 2019

Clinicians’ Guide to Cannabidiol and Hemp Oils Harrison J. VanDolah, Brent A. Bauer, and Karen F. Mauck  Mayo Clinic Proceedings, 2019, 94, (9), 1840-1851 https://doi.org/10.1016/j.mayocp.2019.01.003   Abstract Cannabidiol (CBD) oils are low tetrahydrocannabinol products derived from Cannabis sativa that have become very popular over the past few years. Patients report relief for a variety of conditions, particularly pain, without the intoxicating adverse effects of medical marijuana. In June 2018, the first CBD-based drug, Epidiolex, was approved by the US Food and Drug Administration for treatment of rare, severe epilepsy, further putting the spotlight on CBD and hemp oils. There is a growing body of preclinical and [...]

Lire la suite

Use of Marijuana, Meth, Hallucinogens Up in New SAMHSA Survey, Damian McNamara, August 2019

Use of Marijuana, Meth, Hallucinogens Up in New SAMHSA Survey Damian McNamara Medscape - Aug 22, 2019 Medscape Medical News © 2019 https://www.medscape.com/viewarticle/917131?nlid=131240_2052&src=WNL_mdplsnews_190823_mscpedit_psyc&uac=292598PZ&spon=12&impID=2070816&faf=1 Almost 1 million more Americans ages 12 or older reported using marijuana in their lifetime in 2018 than in 2017, according to new data from a national survey. The Substance Abuse and Mental Health Services Administration (SAMHSA) 2018 National Survey on Drug Use and Health Report notes that approximately 1.2 million more people reported use of hallucinogens, which include LSD, PCP, and Ecstasy, compared with 2017. In addition, about 170,000 more people used methamphetamine. Not all substance use increased year over year. For example, 187,000 fewer adolescent and adult Americans [...]

Lire la suite

Ibogaine : A Novel Anti-Addictive Compound. A Comprehensive Literature Review, Jonathan Freedlander, 2003

Ibogaine : A Novel Anti-Addictive Compound. A Comprehensive Literature Review Jonathan Freedlander Journal of Drug Education and Awareness, 2003 https://www.researchgate.net/publication/287670047_Ibogaine_A_novel_anti-addictive_compound   Introduction and History Ibogaine is a naturally occurring indole alkaloid, found in a variety of African shrubs of the Tabernathe genus (Obach, Pablo, and Mash, 1998). The root of the Tabernanthe iboga plant (also known as eboga) is the most frequently cited source of ibogaine, and this plant contains 11 other known psychoactive constituents (Popik, and Skolnick, 1999). Chemically, ibogaine is classified as a tryptamine, being a rigid analogue of melatonin, and is structurally similar to harmaline, another natural alkaloid and psychedelic (Xu et al, [...]

Lire la suite

Opioïdes : le cannabidiol pour réduire la dépendance ?, RESPADD, Actualités des Addictions n°100, juillet 2019

Opioïdes  : le cannabidiol pour réduire la dépendance ? Le cannabidiol (CBD) réduit le craving et l'anxiété chez les personnes ayant des antécédents d'abus d'héroïne/opioïdes, suggérant un rôle possible du cannabis ou de son agent le cannabidiol dans la réduction de la dépendance aux opioïdes. C’est la conclusion de cette étude réalisée à l’Icahn School of Medicine du Mont Sinaï (New York), présentée dans l'American Journal of Psychiatry. L'étude confirme également les effets anti-stress du CBD avec une baisse de la fréquence cardiaque et du taux de cortisol induites par les stimuli de drogues.   La grande disponibilité des opioïdes sur prescription ces [...]

Lire la suite

The tripping point : The potential role of psychedelic-assisted therapy in the response to the opioid crisis, Elena Argento et al., 2018

The tripping point : The potential role of psychedelic-assisted therapy in the response to the opioid crisis Elena Argento, Kenneth W. Tupper, M. Eugenia Socias International Journal of Drug Policy, 2019,  66, 80–81 https://doi.org/10.1016/j.drugpo.2018.11.006 0955-3959/ © 2018 Elsevier B.V. All rights reserved A B S T R A C T The increasing contamination of the drug supply with illicitly manufactured fentanyl and related analogs in North America has resulted in the most severe drug-overdose crisis in history. Available pharmaco-therapy options for the treatment of opioid use disorder have had limited success in curbing the current crisis, and a growing body of evidence highlights the need for [...]

Lire la suite